The sudden termination of the navacaprant program triggered a 35% reduction in the company's workforce. Neumora estimates these layoffs will generate $10 million in annual savings, a move intended to preserve capital for the remainder of its drug pipeline. Despite the setback, the firm maintains that current cash and equivalents provide sufficient runway to fund operations through the third quarter of 2027.

Investors reacted sharply to the news, leading to a premarket trading halt on Monday. Neumora shares had closed at $1.78 on Friday before the clinical data prompted the strategic pivot.